Columbia Laboratories Inc. (Nasdaq: CBRX) today announced the appointment of Jonathan B. Lloyd Jones, ACA, MBA, as Vice President, Finance, Chief Financial Officer, Treasurer and Secretary, effective January 21. He will be based at Columbia’s corporate headquarters, which will be relocated to the area of Boston, Massachusetts during the first half of 2013.
Mr. Lloyd Jones joins Columbia with over 25 years of corporate development and finance experience. He has led negotiations, valuation and diligence teams that developed and executed over $2 billion of biotechnology and pharmaceutical company mergers and acquisitions, financing and licensing transactions. Most recently, he served as chief financial officer and vice president of corporate development at TetraLogic Pharmaceuticals, a venture capital-funded biotechnology company. From 2006 to 2010, Mr. Lloyd Jones was vice president of finance at TransMolecular, Inc. During the prior 10 years, he was employed by Genzyme as a senior director of corporate development. Earlier in his career Mr. Lloyd Jones headed banking and financial operations at The Royal Bank of Scotland (Nassau) Ltd., part of the Royal Bank of Scotland Group. Mr. Lloyd Jones holds an MBA degree from The Wharton School of the University of Pennsylvania and is a member of the Institute of Chartered Accountants in England and Wales (ICAEW).
Mr. Lloyd Jones replaces Lawrence A. Gyenes, formerly Columbia’s Chief Financial Officer, who will remain with the Company through January 31, 2013, which will also be Michael McGrane’s last day as Columbia’s General Counsel. Messrs. Gyenes and McGrane will remain available to the Company to ensure a smooth transition.
Frank Condella, Columbia’s President and CEO, said, “I want to thank Larry and Mike for their many contributions, which have enabled the Company to successfully transition to a profitable drug delivery company. I speak for the full Board of Directors in wishing them well.
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV